Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441159 | 0.84 | SCN3A (0.42) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420025 | 0.84 | SCN3A (0.42) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420385 | 0.83 | L3MBTL1 (0.38) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420388 | 0.83 | L3MBTL1 (0.38) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420391 | 0.83 | L3MBTL1 (0.38) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420045 | 0.81 | GRM5 (0.39) | — | |
| SCHEMBL15420285 | 0.81 | MAOB (0.37) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15441698 | 0.81 | MAOB (0.37) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15420805 | 0.81 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL15420637 | 0.80 | PARP15 (0.45) | ALDH1A1KDM4EL3MBTL1GAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | ALDH1A1 143/4885KDM4E 2112/4885MEN1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.